Therapies that consist of inhibition of MEK/ERK in combination with JAK2 inhibition or perhaps with other promising targeted agents for MPN could improve JAK2 inhibitor therapy for MPN patients or lead to JAK2 inhibitor independent therapeutic approaches. This evidence concerns the gene MAP2K7 and myeloproliferative disorder.